How to manage metabolic syndrome: Clinical approach based on cardiovascular risk profile

Andrea Ferrucci, Sebastiano Sciarretta, Valentina Valenti, Giuliano Tocci

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Metabolic syndrome (MS) is a complex clinical condition, initially described as 'metabolic syndrome X', characterised by the presence in the same individual of multiple metabolic and cardiovascular traits, typically high blood pressure, abdominal obesity, lipid profile abnormalities, insulin resistance and glucose intolerance. More recently, other features have been proposed; in particular, chronic proinflammatory and pro-thrombotic states seem to further characterise MS. Because of its multifactorial pathogenesis, a unitary clinical management of MS is still debated and physicians tend to make individual choices. In particular, the threshold for treatment initiation is rather heterogeneous. However, a large body of observational studies have demonstrated that patients with MS have an increased incidence of major cardiovascular events, such as acute myocardial infarction and ischemic stroke, particularly in those patients with a high-risk profile (hypertensive patients with target organ damage or diabetes mellitus). An aggressive therapeutic approach for reducing global cardiovascular risk is effective in these subgroups. On the other hand, the lack of specific international guidelines, consisting of a diagnostic and therapeutic algorithm with accurate cardiovascular risk stratification, makes the clinical management of patients with MS by primary physicians difficult and not uniform. In particular, while there is convincing evidence that the progressive addition of components of MS increases cardiovascular risk, there are no consistent indications regarding treatment priorities and strategies. In this article we propose a global risk-based stratification, aimed at identifying 'low-risk' and 'high-risk' patients within those presenting the MS. This approach may prove to be of particular efficacy in clinical practice to identify patients with MS with different degrees of cardiovascular disease risk profile. This approach may also be helpful to develop therapeutic strategies based on global cardiovascular risk profile.

Original languageEnglish
Pages (from-to)231-238
Number of pages8
JournalHigh Blood Pressure and Cardiovascular Prevention
Volume12
Issue number4
DOIs
Publication statusPublished - 2005

Fingerprint

Metabolic Syndrome X
Physicians
Therapeutics
Glucose Intolerance
Abdominal Obesity
Observational Studies
Insulin Resistance
Diabetes Mellitus
Cardiovascular Diseases
Stroke
Myocardial Infarction
Guidelines
Hypertension
Lipids
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

How to manage metabolic syndrome : Clinical approach based on cardiovascular risk profile. / Ferrucci, Andrea; Sciarretta, Sebastiano; Valenti, Valentina; Tocci, Giuliano.

In: High Blood Pressure and Cardiovascular Prevention, Vol. 12, No. 4, 2005, p. 231-238.

Research output: Contribution to journalArticle

@article{b489902c4da04eaf89f247e55f1bddb6,
title = "How to manage metabolic syndrome: Clinical approach based on cardiovascular risk profile",
abstract = "Metabolic syndrome (MS) is a complex clinical condition, initially described as 'metabolic syndrome X', characterised by the presence in the same individual of multiple metabolic and cardiovascular traits, typically high blood pressure, abdominal obesity, lipid profile abnormalities, insulin resistance and glucose intolerance. More recently, other features have been proposed; in particular, chronic proinflammatory and pro-thrombotic states seem to further characterise MS. Because of its multifactorial pathogenesis, a unitary clinical management of MS is still debated and physicians tend to make individual choices. In particular, the threshold for treatment initiation is rather heterogeneous. However, a large body of observational studies have demonstrated that patients with MS have an increased incidence of major cardiovascular events, such as acute myocardial infarction and ischemic stroke, particularly in those patients with a high-risk profile (hypertensive patients with target organ damage or diabetes mellitus). An aggressive therapeutic approach for reducing global cardiovascular risk is effective in these subgroups. On the other hand, the lack of specific international guidelines, consisting of a diagnostic and therapeutic algorithm with accurate cardiovascular risk stratification, makes the clinical management of patients with MS by primary physicians difficult and not uniform. In particular, while there is convincing evidence that the progressive addition of components of MS increases cardiovascular risk, there are no consistent indications regarding treatment priorities and strategies. In this article we propose a global risk-based stratification, aimed at identifying 'low-risk' and 'high-risk' patients within those presenting the MS. This approach may prove to be of particular efficacy in clinical practice to identify patients with MS with different degrees of cardiovascular disease risk profile. This approach may also be helpful to develop therapeutic strategies based on global cardiovascular risk profile.",
author = "Andrea Ferrucci and Sebastiano Sciarretta and Valentina Valenti and Giuliano Tocci",
year = "2005",
doi = "10.2165/00151642-200512040-00005",
language = "English",
volume = "12",
pages = "231--238",
journal = "High Blood Pressure and Cardiovascular Prevention",
issn = "1120-9879",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - How to manage metabolic syndrome

T2 - Clinical approach based on cardiovascular risk profile

AU - Ferrucci, Andrea

AU - Sciarretta, Sebastiano

AU - Valenti, Valentina

AU - Tocci, Giuliano

PY - 2005

Y1 - 2005

N2 - Metabolic syndrome (MS) is a complex clinical condition, initially described as 'metabolic syndrome X', characterised by the presence in the same individual of multiple metabolic and cardiovascular traits, typically high blood pressure, abdominal obesity, lipid profile abnormalities, insulin resistance and glucose intolerance. More recently, other features have been proposed; in particular, chronic proinflammatory and pro-thrombotic states seem to further characterise MS. Because of its multifactorial pathogenesis, a unitary clinical management of MS is still debated and physicians tend to make individual choices. In particular, the threshold for treatment initiation is rather heterogeneous. However, a large body of observational studies have demonstrated that patients with MS have an increased incidence of major cardiovascular events, such as acute myocardial infarction and ischemic stroke, particularly in those patients with a high-risk profile (hypertensive patients with target organ damage or diabetes mellitus). An aggressive therapeutic approach for reducing global cardiovascular risk is effective in these subgroups. On the other hand, the lack of specific international guidelines, consisting of a diagnostic and therapeutic algorithm with accurate cardiovascular risk stratification, makes the clinical management of patients with MS by primary physicians difficult and not uniform. In particular, while there is convincing evidence that the progressive addition of components of MS increases cardiovascular risk, there are no consistent indications regarding treatment priorities and strategies. In this article we propose a global risk-based stratification, aimed at identifying 'low-risk' and 'high-risk' patients within those presenting the MS. This approach may prove to be of particular efficacy in clinical practice to identify patients with MS with different degrees of cardiovascular disease risk profile. This approach may also be helpful to develop therapeutic strategies based on global cardiovascular risk profile.

AB - Metabolic syndrome (MS) is a complex clinical condition, initially described as 'metabolic syndrome X', characterised by the presence in the same individual of multiple metabolic and cardiovascular traits, typically high blood pressure, abdominal obesity, lipid profile abnormalities, insulin resistance and glucose intolerance. More recently, other features have been proposed; in particular, chronic proinflammatory and pro-thrombotic states seem to further characterise MS. Because of its multifactorial pathogenesis, a unitary clinical management of MS is still debated and physicians tend to make individual choices. In particular, the threshold for treatment initiation is rather heterogeneous. However, a large body of observational studies have demonstrated that patients with MS have an increased incidence of major cardiovascular events, such as acute myocardial infarction and ischemic stroke, particularly in those patients with a high-risk profile (hypertensive patients with target organ damage or diabetes mellitus). An aggressive therapeutic approach for reducing global cardiovascular risk is effective in these subgroups. On the other hand, the lack of specific international guidelines, consisting of a diagnostic and therapeutic algorithm with accurate cardiovascular risk stratification, makes the clinical management of patients with MS by primary physicians difficult and not uniform. In particular, while there is convincing evidence that the progressive addition of components of MS increases cardiovascular risk, there are no consistent indications regarding treatment priorities and strategies. In this article we propose a global risk-based stratification, aimed at identifying 'low-risk' and 'high-risk' patients within those presenting the MS. This approach may prove to be of particular efficacy in clinical practice to identify patients with MS with different degrees of cardiovascular disease risk profile. This approach may also be helpful to develop therapeutic strategies based on global cardiovascular risk profile.

UR - http://www.scopus.com/inward/record.url?scp=33644671566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644671566&partnerID=8YFLogxK

U2 - 10.2165/00151642-200512040-00005

DO - 10.2165/00151642-200512040-00005

M3 - Article

AN - SCOPUS:33644671566

VL - 12

SP - 231

EP - 238

JO - High Blood Pressure and Cardiovascular Prevention

JF - High Blood Pressure and Cardiovascular Prevention

SN - 1120-9879

IS - 4

ER -